![]() This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error-all of which support quality patient care.Įndo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Ready-to-use, or RTU, products help streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This acquisition is separate from Endo's previously announced exclusive licensing agreement with Nevakar. The one-time payment is expected to be expensed immediately in the second quarter as acquired in-process research and development costs. Under the terms of the agreement, EVL purchased the six product candidates from Nevakar Injectables for a one-time payment of $35 million. Endo's Par Sterile Products business will commercialize the products in the United States. With the acquisition, Endo controls all remaining development, approval, launch and commercialization activities for these product candidates. The product candidates are in various stages of development, with the first launch expected in 2025. "We look forward to further developing and bringing these durable and differentiated products to market-and to the healthcare providers and patients who need them." The Attorney General believes the complaint should be made available to the public in its entirety and efforts to keep it confidential will only prolong and diminish Endo’s accountability for its conduct."These six product candidates that would be used in critical care settings meaningfully expand Endo's ready-to-use injectable product pipeline," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. The order sealed by the judge allows the seal to expire in 10 days unless Endo acts to extend it. The Attorney General requested the complaint be filed under a temporary seal because Endo claims the information produced during the State’s investigation is confidential. Endo provided significant funding to other third-party groups and subsequently relied on material generated by those groups without disclosing the financial relationship. The State also has reason to believe Endo used the recommendations and educational materials of third-party groups like the American Pain Foundation without disclosing that Endo was by far the biggest donor to the Foundation and provided more than half of its total funding. The Complaint alleges that Endo also knew the dangers of its opioid products, including increased risks of respiratory depression and death in elderly patients, and failed to clearly disclose those risks while it specifically targeted patients in that age group. It did this despite evidence to the contrary, including the FDA’s explicit rejection of Endo’s claim that Opana ER was resistant to abuse as well as overwhelming evidence that Opana ER was being abused throughout Tennessee. The allegations in the State’s 180-page complaint detail how Endo deceptively marketed its opioid products as being less addictive and more effective than others on the market. “Endo has repeatedly refused to take responsibility for its unconscionable conduct, which is why we are taking this action.” ![]() “Our Office has conducted an extensive investigation into Endo’s unlawful marketing practices which included targeting vulnerable populations like the elderly,” said Tennessee Attorney General Herbert H. The State’s lawsuit, filed in Knoxville, alleges Endo violated the Tennessee Consumer Protection Act and contributed to a devastating public health crisis in Tennessee. (Endo) for making unlawful and false claims about the safety and benefits of its opioid products. Slatery III today sued Endo Pharmaceuticals and Endo Health Solutions Inc. Here are details from the news release by Attorney General Herbert Slatery’s office:Īttorney General Herbert H. ![]() The AG’s office says Endo violated the Tennessee Consumer Protection Act and contributed to a devastating health crisis in Tennessee. The Tennessee Attorney General is suing Endo for making unlawful and false claims about the safety and benefits of its opioid products. TN Attorney General sues opioid maker Endo Pharmaceuticals (photo courtesy Times News)Įndo Pharmaceuticals, the same company which was at the center of a $193 million settlement with one of James Hoyer’s whistleblower clients, is now facing another major legal battle.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |